Main – An updated COVID-19 vaccine is tailored by Pfizer-BionTech to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older. You should NOT get COMIRNATY® (COVID-19 Vaccine, mRNA) if you had a severe allergic reaction to a previous dose of COMIRNATY or any Pfizer-BioNTech COVID-19 vaccine or to any ingredient …
Expanding scope of practice will connect Ontarians to faster and easier access to care TORONTO — The Ontario government is making it easier and more convenient for people to connect to care by expanding the role of registered nurses to prescribe medications, after meeting specific requirements, for certain conditions such as contraception, immunizations, smoking cessation, and topical wound care in …
Ontarians strongly encouraged to get their COVID-19 vaccine and flu shot TORONTO — Starting October 30, Ontarians will be able to receive their free flu shot and the new, most recent COVID-19 vaccine at local pharmacies, public health units and primary health care providers across the province. Staying up to date on vaccinations continues to be the best way for …
Washington (CNN) – Vaccine advisers of the US Centers for Disease Control and Prevention, independent in nature, have voted 13-1 to recommend updated Covid-19 vaccines for all Americans aged 6 months and older. The recommendations, made by the Advisory Committee on Immunization Practices (ACIP) and await approval from the CDC director, Dr Mandy Cohen, according to CNN. The Advisory Committee …
Health Canada submission follows international recommendations to develop monovalent XBB.1.5 COVID-19 vaccines Moderna is prepared to deliver updated COVID-19 vaccines in time for the fall 2023 vaccination season TORONTO – Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that it has initiated the filing of a rolling New Drug Submission (NDS) to Health Canada …
Geneva -The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continues to meet regularly to assess the implications of SARS-CoV-2 evolution for COVID-19 vaccine antigen composition and advise WHO on whether changes are needed to the antigen composition of future COVID-19 vaccines. In April 2023, the TAG-CO-VAC indicated that the advisory group would convene at least twice in 2023: once in …
